In a Glasgow conference hall, where the HIV community gathers to measure its progress against a disease that has tested it for four decades, researchers presented a question that matters to anyone living with the virus: can a simplified single-tablet treatment still hold when the virus has already learned some defensive tricks? The phase 3 ARTISTRY-2 trial suggests it can, reporting that bictegravir-lenacapavir, sold as Bixlenvo, kept the virus suppressed over 48 weeks even in people who carried resistance mutations before they began. The finding is encouraging, but it arrives as a conference
Bixlenvo Keeps HIV Viral Suppression Even Where Resistance Mutations Pre-Exist, ARTISTRY-2 Finds
One case of emergent resistance among 383 people taking the new tablet
Mark
So what did ARTISTRY-2 actually show?
Mimi
That switching to bictegravir-lenacapavir kept viral suppression high over 48 weeks, even in people who already had resistance-associated mutations at baseline. Those mutations made no significant difference to either regimen.
Mark
How big was the trial?
Mimi
574 participants. 383 of them took BIC/LEN, and the comparison group stayed on Biktarvy.
Luke
I'd flag that the comparison group size isn't stated in what we have. We're inferring it from the totals.
Mark
And the resistance that emerged during treatment?
Mimi
One case among the 383 on BIC/LEN. Phenotypic susceptibility to the study drugs was maintained.
Luke
One case is reassuring, but it's a small count. Also, we don't know how many people had baseline mutations, so the 'no effect' result could rest on a small subgroup.
Mark
Is that a weakness?
Luke
It's an unknown. A P value above 0.05 means no detectable difference, not proof of none, especially in subgroups.
Mimi
Which is why the full paper matters. It should give the mutation types and the suppression percentages.
Luke
Right. This is a conference presentation, not yet peer reviewed, and the trial was sponsored by the maker of both regimens.
O Pulso
- A pre-existing resistance mutation threatened to undermine a newer HIV regimen, and the trial tested whether it actually would.
- Among 574 participants in ARTISTRY-2, baseline mutations made no statistically significant difference to outcomes in either treatment arm.
- Resistance emerging during treatment was almost absent, with only one case among 383 people taking BIC/LEN.
- The results remain a conference presentation, so independent scrutiny and peer review must confirm them before clinical practice shifts.
In a Glasgow conference hall, where the HIV community gathers to measure its progress against a disease that has tested it for four decades, researchers presented a question that matters to anyone living with the virus: can a simplified single-tablet treatment still hold when the virus has already learned some defensive tricks? The phase 3 ARTISTRY-2 trial suggests it can, reporting that bictegravir-lenacapavir, sold as Bixlenvo, kept the virus suppressed over 48 weeks even in people who carried resistance mutations before they began. The finding is encouraging, but it arrives as a conference report, and the wider medical world will wait for the full published record before deciding what it means for the clinic.
The findings were presented at HIV Glasgow 2026 as abstract 048, and they answer a practical question for people living with HIV. Can a regimen that works well for most patients still succeed when resistance mutations were already present before treatment began? According to the ARTISTRY-2 trial, it can.
The regimen, bictegravir-lenacapavir, marketed by Gilead Sciences as Bixlenvo, combines two antiretrovirals in a single tablet. The trial compared people who switched to it with people who stayed on the existing three-drug regimen, bictegravir, emtricitabine, and tenofovir alafenamide, sold as Biktarvy. Of 574 participants, 383 received BIC/LEN.
Over 48 weeks, baseline resistance mutations had no significant effect on how well either regimen worked. Viral suppression remained high for BIC/LEN, including among participants who carried those mutations. Emerging resistance during treatment was also rare, with a single case among the 383 BIC/LEN recipients, and the virus stayed susceptible to the drugs in laboratory testing.
The report is brief, and it leaves open details that will matter, such as which mutations were present, how many people carried them, and the exact suppression rates. Until the full peer-reviewed publication and independent analysis arrive, the result is a promising signal rather than a reason to change treatment.
The finding comes from a conference room in Glasgow, where results from the phase 3 ARTISTRY-2 trial were presented at HIV Glasgow 2026 (abstract 048). The question behind them is a practical one for people living with HIV: does a new single-tablet regimen still work when resistance-associated mutations were already present before treatment began? According to the data, it does.
The regimen is bictegravir-lenacapavir, known as BIC/LEN and sold as Bixlenvo by Gilead Sciences. It combines two antiretrovirals in one tablet. ARTISTRY-2 tested it as a switch option, comparing people who moved to BIC/LEN with people who stayed on bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF), which Gilead markets as Biktarvy.
The trial enrolled 574 participants with HIV. Of those, 383 received BIC/LEN. The rest, by implication, continued on the existing three-drug regimen, though the source does not give that number.
Researchers looked at whether baseline resistance-associated mutations, those already detectable at the start of the study, changed how well either regimen worked over 48 weeks. They did not. The presence of such mutations had no significant effect on efficacy in either group (P>0.05). Viral suppression rates stayed high for BIC/LEN even in participants who carried them.
The second finding concerns resistance that arises during treatment. Treatment-emergent resistance-associated mutations were rare among people taking BIC/LEN: one case among the 383 participants. In that setting, phenotypic susceptibility to the study drugs was maintained, meaning the virus still responded to the medicines in laboratory testing.
The report is brief and comes from a conference presentation rather than a full publication. It does not detail which specific mutations were present at baseline, how many participants carried them, or the exact suppression percentages. Those numbers will matter for judging how far the result can be generalized.
What to watch for next is the full peer-reviewed publication of ARTISTRY-2, along with independent scrutiny of the data. Until then, the headline result stands as an encouraging signal that the regimen holds up against pre-existing resistance, not yet a basis for changing clinical practice.
Citações Notáveis
Baseline resistance-associated mutations did not affect the efficacy of either regimen during 48 weeks of treatment.— ARTISTRY-2 findings, presented at HIV Glasgow 2026
Quer a matéria completa?
Leia o original em European AIDS Treatment Group ↗